MANF identified as a rejuvenating factor in parabiosis
Buck researchers also harness an innate repair mechanism to protect against liver damage in aging mice and extend lifespan in flies
Credit: Joana Neves, Ph.D., Buck Institute for Research on Aging
Older mice who are surgically joined with young mice in order to share a common bloodstream get stronger and healthier, making parabiosis one of the hottest topics in age research. Publishing in Nature Metabolism, researchers from the Buck Institute report that MANF (mesencephalic astrocyte-derived neurotrophic factor) is one of the factors responsible for rejuvenating the transfused older mice. Researchers also show the naturally-occurring, evolutionarily-conserved repair mechanism protects against liver damage in aging mice and extends lifespan in flies.
“We know that MANF, which regulates metabolism and immune response in flies, mice and humans, declines with age,” said senior author Heinrich Jasper, PhD, a Buck professor and staff scientist at Genentech. “This research shows that replenishing MANF has promise as an anti-aging treatment although much work remains to be done in order to understand its mechanism of action.”
While researchers have yet to understand why MANF levels decrease with age, Jasper says MANF deficiency has obvious hallmarks. Flies genetically engineered to express less MANF suffered from increased inflammation and shorter lifespans. MANF-deficient mice had increased inflammation in many tissues as well as progressive liver damage and fatty liver disease. Older mice who shared blood with MANF-deficient younger mice did not benefit from the transfusion of young blood.
Buck postdoctoral fellows Pedro Sousa-Victor, PhD, and Joana Neves, PhD, were co-leaders of the study. They zeroed in on MANF and its impact on the liver and metabolism. They found that liver rejuvenation spurred by parabiosis was dependent on MANF. In addition, they showed that supplementing MANF in aging mice slowed liver aging, prevented fatty liver disease in animals on a high fat diet and improved age-related metabolic dysfunction.
“MANF appears to regulate inflammatory pathways that are common to many age-related diseases,” said Neves. “We are hoping its effects extend beyond the liver, we plan to explore this in other tissues.”
“The search for systemic treatments that would broadly delay or prevent age-related diseases remains the holy grail of research in aging,” said Jasper. “Given that MANF appears to modulate the immune system, we are excited to explore the larger implications of its therapeutic use. We are also cautious. There are many tissues and organ systems to evaluate in terms of MANF and we have yet to determine its effects on lifespan in the mouse.”
Citation: MANF regulates metabolic and immune homeostasis in ageing and protects against liver damage
Other Buck researchers involved in the study include Wendy Cedron-Craft, Chen-Yu-Liao, and Rebeccah R. Riley. Other collaborators include Deepak A. Lamba, The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco; P. Britten Ventura and Saul A. Villeda, Department of Anatomy, University of California, San Francisco; Ilya Soifer, Nicholas van Bruggen, and Ganesh A. Kolumam, Calico Life Sciences LLC, South San Francisco, CA.
The work was funded by NIH grants AG052989, AG050104, AG047497, EY025779, and AG055797. Support was also provided by Calico Labs and the Glenn Foundation for Medical Research.
About the Buck Institute for Research on Aging
At the Buck, we aim to end the threat of age-related diseases for this and future generations. We bring together the most capable and passionate scientists from a broad range of disciplines to study mechanisms of aging and to identify therapeutics that slow down aging. Our goal is to increase human health span, or the healthy years of life. Located just north of San Francisco, we are globally recognized as the pioneer and leader in efforts to target aging, the number one risk factor for serious diseases including Alzheimer’s, Parkinson’s, cancer, macular degeneration, heart disease, and diabetes. The Buck wants to help people live better longer. Our success will ultimately change healthcare. Learn more at: https:/
Related Journal Article